Initial clinical evaluation of a New Rocky Mountain spotted fever vaccine of tissue culture origin

M. S. Ascher, C. N. Oster, Philip I Harber, R. H. Kenyon, C. E. Pedersen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Currently available Rocky Mountain spotted fever (RMSF) vaccines are relatively ineffective in preventing infections in humans and contain considerable amounts of contaminating egg protein. A new formalin-inactivated vaccine was prepared by sucrose density gradient centrifugation of the Sheila Smith strain of Rickettsia rickettsii grown in chick embryo cell tissue culture. The new product has greater protective immunogenicity in rhesus monkeys and guinea pigs than commercial vaccines. Six volunteers without immunologic evidence of prior exposure to RMSF received from one to three inoculations of the vaccine diluted 1:10, and there were two benign local reactions. Titers of antibody (determined by microagglutination and indirect fluorescence techniques) increased in all recipients as did lymphocyte transformation responses to specific rickettsial antigen. Ten volunteers were immunized twice with vaccine diluted 1:3; there were no local reactions, and immunologic responses were similar to those in the six volunteers in the first group. The proper dosage and immunization schedule for the vaccine must be determined in further studies.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalJournal of Infectious Diseases
Volume138
Issue number2
StatePublished - 1978
Externally publishedYes

Fingerprint

Rocky Mountain Spotted Fever
Vaccines
Volunteers
Rickettsia rickettsii
Immunization Schedule
Egg Proteins
Inactivated Vaccines
Density Gradient Centrifugation
Chick Embryo
Lymphocyte Activation
Macaca mulatta
Formaldehyde
Sucrose
Guinea Pigs
Cell Culture Techniques
Fluorescence
Antigens
Antibodies
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Initial clinical evaluation of a New Rocky Mountain spotted fever vaccine of tissue culture origin. / Ascher, M. S.; Oster, C. N.; Harber, Philip I; Kenyon, R. H.; Pedersen, C. E.

In: Journal of Infectious Diseases, Vol. 138, No. 2, 1978, p. 217-221.

Research output: Contribution to journalArticle

Ascher, M. S. ; Oster, C. N. ; Harber, Philip I ; Kenyon, R. H. ; Pedersen, C. E. / Initial clinical evaluation of a New Rocky Mountain spotted fever vaccine of tissue culture origin. In: Journal of Infectious Diseases. 1978 ; Vol. 138, No. 2. pp. 217-221.
@article{0f36cb4446e646fbb5efa2a6cc3b812d,
title = "Initial clinical evaluation of a New Rocky Mountain spotted fever vaccine of tissue culture origin",
abstract = "Currently available Rocky Mountain spotted fever (RMSF) vaccines are relatively ineffective in preventing infections in humans and contain considerable amounts of contaminating egg protein. A new formalin-inactivated vaccine was prepared by sucrose density gradient centrifugation of the Sheila Smith strain of Rickettsia rickettsii grown in chick embryo cell tissue culture. The new product has greater protective immunogenicity in rhesus monkeys and guinea pigs than commercial vaccines. Six volunteers without immunologic evidence of prior exposure to RMSF received from one to three inoculations of the vaccine diluted 1:10, and there were two benign local reactions. Titers of antibody (determined by microagglutination and indirect fluorescence techniques) increased in all recipients as did lymphocyte transformation responses to specific rickettsial antigen. Ten volunteers were immunized twice with vaccine diluted 1:3; there were no local reactions, and immunologic responses were similar to those in the six volunteers in the first group. The proper dosage and immunization schedule for the vaccine must be determined in further studies.",
author = "Ascher, {M. S.} and Oster, {C. N.} and Harber, {Philip I} and Kenyon, {R. H.} and Pedersen, {C. E.}",
year = "1978",
language = "English (US)",
volume = "138",
pages = "217--221",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Initial clinical evaluation of a New Rocky Mountain spotted fever vaccine of tissue culture origin

AU - Ascher, M. S.

AU - Oster, C. N.

AU - Harber, Philip I

AU - Kenyon, R. H.

AU - Pedersen, C. E.

PY - 1978

Y1 - 1978

N2 - Currently available Rocky Mountain spotted fever (RMSF) vaccines are relatively ineffective in preventing infections in humans and contain considerable amounts of contaminating egg protein. A new formalin-inactivated vaccine was prepared by sucrose density gradient centrifugation of the Sheila Smith strain of Rickettsia rickettsii grown in chick embryo cell tissue culture. The new product has greater protective immunogenicity in rhesus monkeys and guinea pigs than commercial vaccines. Six volunteers without immunologic evidence of prior exposure to RMSF received from one to three inoculations of the vaccine diluted 1:10, and there were two benign local reactions. Titers of antibody (determined by microagglutination and indirect fluorescence techniques) increased in all recipients as did lymphocyte transformation responses to specific rickettsial antigen. Ten volunteers were immunized twice with vaccine diluted 1:3; there were no local reactions, and immunologic responses were similar to those in the six volunteers in the first group. The proper dosage and immunization schedule for the vaccine must be determined in further studies.

AB - Currently available Rocky Mountain spotted fever (RMSF) vaccines are relatively ineffective in preventing infections in humans and contain considerable amounts of contaminating egg protein. A new formalin-inactivated vaccine was prepared by sucrose density gradient centrifugation of the Sheila Smith strain of Rickettsia rickettsii grown in chick embryo cell tissue culture. The new product has greater protective immunogenicity in rhesus monkeys and guinea pigs than commercial vaccines. Six volunteers without immunologic evidence of prior exposure to RMSF received from one to three inoculations of the vaccine diluted 1:10, and there were two benign local reactions. Titers of antibody (determined by microagglutination and indirect fluorescence techniques) increased in all recipients as did lymphocyte transformation responses to specific rickettsial antigen. Ten volunteers were immunized twice with vaccine diluted 1:3; there were no local reactions, and immunologic responses were similar to those in the six volunteers in the first group. The proper dosage and immunization schedule for the vaccine must be determined in further studies.

UR - http://www.scopus.com/inward/record.url?scp=0018075051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018075051&partnerID=8YFLogxK

M3 - Article

C2 - 355580

AN - SCOPUS:0018075051

VL - 138

SP - 217

EP - 221

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -